Kidney Transplant Rejection
📧 Sign up to get email alerts when something new happens for Kidney Transplant Rejection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2011-06-15FDA Approved: NULOJIX — Original Application (E.R. Squibb & Sons, L.L.C.)
FDA approved NULOJIX (belatacept) via its original biologics license application for the prevention of kidney transplant rejection in adult …
-
CLINICAL_TRIALS trial_result · 2010-10-05Clinical Trial Update: Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys [Phase 2]
A Phase 2 trial evaluating Campath-1H (alemtuzumab) for preventing kidney transplant rejection has completed, with results posted in 2010.
-
FDA approval · 2010-02-02FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for Mycophenolate mofetil submitted by Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2009-10-08FDA Approved: NEORAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for NEORAL (cyclosporine) from Novartis Pharmaceuticals Corporation.
-
FDA approval · 2009-07-22FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil) submitted by Genentech, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2009-06-18FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved Genentech's supplemental application for CellCept (mycophenolate mofetil). The action updates the approved status under a s…
-
FDA approval · 2009-05-19FDA Approved: PROGRAF — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for PROGRAF (tacrolimus) filed by Astellas Pharma US, Inc.
-
FDA approval · 2009-05-06FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's mycophenolate mofetil as an original application; it is used to prevent organ transplant rejection in kidney, liver, and…
-
FDA approval · 2009-05-04FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare's original ANDA for mycophenolate mofetil, authorizing its use to prevent organ transplant rejection in kidne…
-
FDA approval · 2009-02-27FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil) submitted by Genentech, Inc. to modify/expand the approved …
-
CLINICAL_TRIALS trial_result · 2008-12-23Clinical Trial Update: Rituximab for Pediatric Renal Transplant Rejection [Phase 2, Phase 3]
Phase 2 and Phase 3 trials evaluating rituximab for pediatric kidney transplant rejection have completed. The study investigates rituximab a…
-
FDA approval · 2008-12-15FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved Genentech's supplemental application for Cellcept (mycophenolate mofetil), updating the labeling for prevention of organ reject…
-
FDA approval · 2008-12-15FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CellCept (mycophenolate mofetil) submitted by Genentech, Inc.
-
FDA approval · 2008-12-15FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved Genentech's supplemental application for CellCept (mycophenolate mofetil hydrochloride).
-
FDA approval · 2008-10-15FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (Sandoz Inc)
FDA approved the original application for generic mycophenolate mofetil (Sandoz) for prevention of organ transplant rejection in kidney, hea…
-
FDA approval · 2008-05-09FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil hydrochloride) submitted by Genentech, updating the labeling…
-
FDA approval · 2008-05-09FDA Approved: MYFORTIC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for MYFORTIC (mycophenolic acid) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2008-05-09FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Cellcept (mycophenolate mofetil) from Genentech, Inc., indicating an approved modification t…
-
FDA approval · 2008-05-09FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CellCept (mycophenolate mofetil) from Genentech, resulting in changes to the product labeling.
-
FDA approval · 2007-11-02FDA Approved: MYFORTIC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for MYFORTIC (mycophenolic acid) from Novartis Pharmaceuticals Corporation, updating labeling to sup…
-
FDA approval · 2007-08-01FDA Approved: NEORAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for NEORAL (cyclosporine) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2007-07-13FDA Approved: GENGRAF — Supplemental Application (AbbVie Inc.)
FDA approved AbbVie's supplemental application for GENGRAF (cyclosporine), updating the product's approval status under the ANDA process.
-
CLINICAL_TRIALS research · 2007-05-15Clinical Trial Update: Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA) [Phase 4]
Phase 4 clinical trial update evaluating mycophenolate mofetil–based immunosuppressive regimens to optimize renal function in kidney transpl…
-
FDA approval · 2007-01-12FDA Approved: SIROLIMUS — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for sirolimus from Mylan Pharmaceuticals Inc., authorizing a generic version of the immunosuppressan…
-
FDA approval · 2006-06-27FDA Approved: CYCLOSPORINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for Apotex Corp. to market a generic cyclosporine product.